New data shows drug delivery has positive impact on patient compliance

Drug Development and Delivery

Volumn 11, Issue 7, 2011, Pages 30-33

  Hamlen, Steven ^a   MacGregor, Karen ^b  

^a Development of life cycle   (United States)

^b Development and in operational technical support   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; GENERIC DRUG; OLANZAPINE; SELEGILINE;

ADD ON THERAPY; ALLERGIC RHINITIS; ALLERGY; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED RELEASE FORMULATION; DIAGNOSTIC ERROR; DIARRHEA; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG MARKETING; DRUG METABOLISM; DRUG PACKAGING; DRUG SOLUBILITY; EMERGENCY WARD; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LIVER METABOLISM; LONGITUDINAL STUDY; MEDICARE; METABOLITE; MIGRAINE; MUCOSAL ADMINISTRATION; NAUSEA; ORALLY DISINTEGRATING TABLET; PAIN; PARKINSON DISEASE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PILL; REVIEW; SCHIZOPHRENIA; SEX RATIO; SIDE EFFECT; STOMACH ABSORPTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT REFUSAL; UNITED STATES;

EID: 80052580384     PISSN: 15372898     EISSN: 1944818X     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (11)

1. New England Healthcare Institute, Thinking Outside the Pillbox, A System-wide Approach to Improving Patient Medication Adherence for Chronic Disease, August 2009.
2. Month longitudinal patient records analysis conducting by SDI Health, a division of IMS Health, conducted in January, 2011. Study included 1,520 US patients prescribed Zelapar, Eldepryl, or generic Selegiline.
3. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44-47.
4. Thomas Christian SM. Health Care Costs and Patient Noncompliance, EZineArticles.com. September 2010.
5. Prnewswire, website visited: http://www.spraynswallow.com/links January 15, 2004.
6. Technology Catalysts International, Orally Disintegrating Tablet and Film Technologies - 6th Edition. September 2010.
7. IMS Health US sales data, October, 2009 through September 2010. Anti-Parkinson class defined as IMS classification N04A0. Selegiline class defined as Zelapar, Eldepryl, and selegiline generics.
8. Ciprandi G. Clinical utility and patient adherence with ebastine for allergic rhinitis, patient preference and adherence. Volume 4. PubMed Central, October 14, 2010.
9. Clarke A, Johnson ES, Mallard N, Corn TH, Johnston A, Boyce M, Warrington S, MacMahon DG. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm.2003;110(11):1257-1271.
10. Karagianis J, Grossman L, Landry J, et al. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on the body mass index: The PLATYPUS study. Schizophr Res. 2009;113:41-48.
11. Reig AR, Fernandez J P, Cervera JG, Navarro JH, Ferragud MA, Hortal EG. Acceptance survey of a fast dissolving tablet pharmaceutical formulation in allergic patients.satisfaction and expectancies.Allergol Immunopathol. 2006;34:107-112.